Study subjects will use betadine saline sinus rinse for period of 6 weeks.

Chronic Rhinosinusitis (Diagnosis)

Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).

Povidone-Iodine

Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.

Budesonide

St. Paul's Hospital

Betadine Rinses for Chronic Rhinosinusitis Prospective Cohort Study

The Efficacy of Topical Povidone - Iodine Rinses in the Management of Biofilm-associated Chronic Rhinosinusitis

differences in Modified Lund-Kennedy (MLK) endoscopic score after 6 weeks of using Povidone-iodine (PVP-I) sinus rinses.

disease specific quality of life questionnaire score (SNOT-22) in recalcitrant/recurrent CRS patients

We will publish final outcomes as scientific paper.

Amin Javer

Clinical Professor

St. Paul's Hospital, Canada

Infection, Bacterial

Antibiotic Resistant Infection

Diagnostic Self Evaluation

Meningitis, Bacterial

Nosocomial Infection

Neurosurgery dept. University Hospital

Neurosurgery department, University Hospital

Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients.

analyse of different body fluids to detect the focus of infections post neurosurgical fever

Fariba Nayeri

MD, PhD, associated professor

NmVac4-A/C/Y/W-135-DT™ conjugate vaccine

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Test Vaccine

US Licensed Vaccine

Total

Sex: Female, Male

Race/Ethnicity, Customized

Rise in antibody titers in serum at 4 weeks after vaccination, compared to baseline titer for meningococcal serogroups A, C, Y, and W-135. Serum Bactericidal Assay with human complement: Antibody titer ≥1:8 for subjects with titer <1:8 at baseline or a 4-fold rise in antibody levels.

NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
Test Vaccine: NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
US Licensed Vaccine: Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.

Seroresponse (Percent Seroconversion).

Local and systemic rates from Diary Cards filled by the participants.

Test Vaccine - Male

Test Vaccine - Female

US Licensed Vaccine - Male

US Licensed Vaccine - Female

Solicited Adverse Events From Diary Cards

Non solicited local and systemic adverse Event (AE) rates throughout the course of the study, based on laboratory test results, vital signs, examination and questioning the subjects.

Non Solicited Adverse Events

Overall Study

Regulatory Affairs Director

Meningococcal Meningitis

Meningococcal Infections

NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.

Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.

Mid Atlantic Urology Associates LLC

Chesapeake Research Group

IRC Clinics

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

A Phase 2 Double Blind Study to Evaluate Safety and Immunogenicity of Meningococcal Meningitis Serogroups A, C, Y & W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT™) Compared With a Licensed Vaccine

JN-International Medical Corporation

NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.

meningococcal meningitis conjugate vaccine, quadrivalent

Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.

Kings Cardiology Group

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

A Double-Blind, Randomized, Controlled, Two Arm Phase 1 Clinical Trial of the Safety and Immunogenicity of Group A, C, Y & W-135 Meningococcal Polysaccharide DT Conjugate Vaccine: NmVac4-A/C/Y/W-135-DT™

local and systemic rates throughout the course of the study

polysaccharide/sakit kepala

Betadine Rinses for Chronic Rhinosinusitis Prospective Cohort Study

Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients.

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

Database tanaman obat terlengkap yang didukung oleh sains